MARKET NEWS

MilliporeSigma Launches BioContinuum Seed Train Platform for Intensified Upstream Processes
VUMC & Roivant Social Ventures Announce Collaboration to Develop Therapies for Underserved Populations
Protega Pharmaceuticals LLC Announces Commercialization of Oxycodone Hydrochloride Tablets CII in the US
Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3
VectorBuilder to Invest $30 million to Build the World’s First AAV Superbank
PDS Biotech Announces Efficacy & Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head & Neck Cancer

  FEATURED EDITORIAL

  COMPANY PROFILE

Celanese works closely with you as a strategic partner to create innovative controlled-release dosage forms for biologics and small molecules to meet the goals of patient-centric therapies, improved medicine and better healthcare economics. Our scientists and engineers are there from concept to commercialization, providing development services, material supply aligned with GMP principles and regulatory support through our state-of-the art development and feasibility lab. Our objective is to help our customers reduce R&D time and improve the likelihood of successful drug commercialization. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Alvotech Initiates Patient Study for Proposed Biosimilar for Eylea

Alvotech Initiates Patient Study for Proposed Biosimilar for Eylea

Alvotech recently announced the initiation of the company’s confirmatory clinical study for AVT06 (aflibercept), a biosimilar candidate to Eylea…..

Insilico Medicine Identified Multiple New Targets for ALS Using its AI-Driven Target Discovery Engine

Insilico Medicine Identified Multiple New Targets for ALS Using its AI-Driven Target Discovery Engine

Insilico Medicine recently announced the company has identified multiple unreported potential therapeutic targets for amyotrophic lateral sclerosis (ALS), using its proprietary AI-driven target discovery engine….

Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase 3 Part A Clinical Trial

Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase 3 Part A Clinical Trial

Akari Therapeutics, Plc recently announced a patient has completed the course of investigational nomacopan treatment in the open-label, multi-center Phase 3 Part A clinical trial in pediatric hematopoietic stem….

Absci Enters Multi-Program Collaboration With Emerging Biotech Partner

Absci Enters Multi-Program Collaboration With Emerging Biotech Partner

Absci Corporation recently announced it has entered into a collaboration agreement with an undisclosed biotech partner. The partner is a stealth-mode company, led by….

  WHITEPAPERS & WEBINARS

WEBINAR - Hot-Melt Granulation Technology for Lipid-Based Pharmaceuticals

WEBINAR - Hot-Melt Granulation Technology for Lipid-Based Pharmaceuticals

Join our experts Dr. Mandar Kodgule, Dr. Rahul Aware, and Dr. Agnivesh Shrivastava live as they take you through compelling case studies, current trends and developments, and insights on mastering the design of hot-melt granulation process.

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

  WHITEPAPERS & WEBINARS

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

This white paper evaluates the viscosity-reducing capacities of excipients and excipient combinations. It shows the over-additive effect of using two excipients together and addresses how excipients’ viscosity-reducing ability depends on pH. The results show the effect of protein viscosity on …

WHITEPAPER - Protecting Workers and the Environment: Facilities and Processes Key to Safely Making Highly Potent Drug Products

WHITEPAPER - Protecting Workers and the Environment: Facilities and Processes Key to Safely Making Highly Potent Drug Products

Highly potent APIs (HPAPI) are rapidly growing in the pharmaceutical industry. Manufacturing solid oral dosage forms (SOD) containing HPAPIs requires specific knowledge, skills, and precision without compromising environmental or worker safety.

Enteris BioPharma’s HPAPI manufacturing facility was custom-built with comprehensive …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 27 – Controlled Release
August 3 – Analytical Testing